Sign in →

Test Code VIPP Vasoactive Intestinal Polypeptide, Plasma

Reporting Name

Vasoactive Intestinal Polypeptide,P

Useful For

Detection of vasoactive intestinal polypeptide producing tumors in patients with chronic diarrheal diseases

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Specimen Type

Plasma EDTA


Advisory Information


This test should not be requested on patients who have recently received radioactive material.



Specimen Required


Patient Preparation: Fasting (8 hours)

Collection Container/Tube: Lavender top (EDTA)

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL

Collection Instructions: Centrifuge and freeze immediately.


Specimen Minimum Volume

0.55 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Plasma EDTA Frozen 90 days

Reference Values

<75 pg/mL

Day(s) and Time(s) Performed

Monday, Tuesday, Wednesday; 2 p.m.

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information

84586

LOINC Code Information

Test ID Test Order Name Order LOINC Value
VIP Vasoactive Intestinal Polypeptide,P 3125-2

 

Result ID Test Result Name Result LOINC Value
8150 Vasoactive Intestinal Polypeptide,P 3125-2

Clinical Reference

1. Smith SL, Branton SA, Avino AJ, et al: Vasoactive intestinal polypeptide secreting islet cell tumors: a 15-year experience and review of the literature. Surgery 1998 Dec;124(6):1050-1055 (Review)

2. Ghaferi AA, Chojnacki KA, Long WD, et al: Pancreatic VIPomas: subject review and one institutional experience. J Gastrointest Surg 2008 Feb;12(2):382-393

3 Eisenhofer G, Grebe S, Cheung NK, et al: Ch 63 Monoamine-Producing Tumors. In Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Sixth edition. Edited by N Rafai, AR Horvath, CT Wittwer. Elsevier, 2018, pp 1421

Method Description

Vasoactive intestinal polypeptide (VIP) in the patient sample competes with labeled ([125]I) VIP for a limited number of primary antibody binding sites during a 24-hour incubation. Antibody-bound VIP is separated from the unbound portion by a goat anti-rabbit secondary antibody. Centrifugation brings down the heavy antibody complexes while unbound antigen remains in solution and is discarded. The amount of labeled antigen bound to the antibody is inversely proportional to the amount of VIP present in the patient sample. The (125)I signal is counted on a gamma counter and the counts per minute are used to calculate percent of maximum binding and construct a standard curve.(Unpublished Mayo method)

Analytic Time

3 days

Reject Due To

Gross hemolysis Reject
Gross lipemia Reject
Gross icterus OK

Method Name

Radioimmunoassay (RIA)